In this study, we tested the pan-PI3K/mTOR inhibitor, gedatolisib, and node-selective inhibitors for PI3Kα (alpelisib), AKT (capivasertib) and mTORC1 (everolimus) to compare the functional effect of inhibiting single versus multiple PAM pathway nodes in a panel of breast cancer cell lines. The gene discussed is PIK3CG; the disease is breast carcinoma.